Khondrion Doses First Patient in Phase 2b Trial Testing Sonlicromanol for Mitochondrial Diseases

Print Friendly, PDF & Email

Working toward MELAS treatment, clinical trial:   Khondrion has dosed the first patient in a Phase 2b clinical trial evaluating sonlicromanol , its lead investigational therapy for treating a range of mitochondrial diseases in adults. Sonlicromanol is being developed as a treatment for MELAS — mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes — and MIDD , […]